REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pherin Pharmaceuticals, Inc. reports that recent clinical trial results from a Phase II study showed that PH80, a novel compound patented by Pherin Pharmaceuticals, administered intranasally in aerosol form demonstrated significant benefits in the treatment of symptoms of PMS. Based on the positive Phase II study results, Pherin Pharmaceuticals is programming a Phase III pivotal study to further evaluate PH80 benefits in patients with PMS.
